Research
Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports
The Brief
- Tirzepatide (Zepbound), a once-weekly injectable, acts on two gut hormone targets, GIP and GLP-1.
- A new clinical trial reports that more than half of treated teens moved below the obesity threshold.
Why it matters
The trial suggests a dual-action drug can shift obesity status in adolescents, which is relevant to how pediatric obesity treatment is studied and managed.
Who’s affected
- clinicians and researchers in pediatric obesity
- families of teenagers with obesity
Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together…